An interventional study of Transcatheter Cutting Balloon therapy and High Pressure Balloon Angioplasty in Pulmonary Artery Stenosis, sponsored by Boston Children's Hospital. Completed at 6 sites in United States. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the safety and efficacy of transcatheter Cutting Balloon therapy for branch pulmonary artery stenosis resistant to low pressure dilation.
The proposed study will be a prospective, multi-center, randomized, blinded trial comparing 2 treatments for pulmonary artery stenosis. Specifically, vessels that fail to respond to balloon inflation at 8 ATM will be individually randomized to 1 of 2 treatment pathways. In the first treatment pathway, the vessel is dilated using a CB, followed by additional low pressure balloon dilation (\< 8ATM). In the second pathway,the vessel is dilated with high pressure balloon angioplasty, with balloon inflation pressures exceeding 15 ATM. Cross-over therapy will be permitted for failed high pressure treatment starting with enrollment of patient #15. The primary outcome assessment for efficacy will be a comparison of percent change in minimum lumen diameter before and after randomized therapy, as determined by a core laboratory blinded to pathway assignment. The primary outcome assessment for safety will be a comparison of the proportion of vessel dilations resulting in any serious adverse events, as determined by the Data and Safety Monitoring Board. Patient-level safety endpoints will also be tabulated. Patients can have multiple vessels enrolled; analytical techniques will adjust for potential intra-patient correlation.
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient Inclusion Criteria (Determined Prior to Cardiac Catheterization)
a. At least 1 branch pulmonary artery stenosis referred for planned catheterization for PA dilation b. At least one of the following: i.greater than one half systemic right ventricular pressure ii. regional decrease in pulmonary blood flow by lung scan iii. elevated pulmonary artery pressures (> 20 mmHg MPAP) iv. cyanosis at least in part due to PA stenosis c. of patient and/or parent/guardian; assent of mature minors d. Agreement to participate in protocol, including follow-up testing
Vessel Inclusion Criteria (Determined During Cardiac Catheterization)
Exclusion Criteria:
3. Patient Exclusion Criteria (Determined Prior to Cardiac Catheterization)
Vessel Exclusion Criteria (Determined During Cardiac Catheterization)
i. balloon inflation for the purpose of expanding the diameter of the stent along its length with no residual waist proximal or distal to the stent edges ii. balloon inflation resulting in waist formation within the edges of a stent iii. dilation of a vessel through the cells of a stent c. Unifocalized nor non-unifocalized systemic to pulmonary artery collaterals. d. A vessel requiring therapy at a site not amenable to delivery or safe positioning of a Cutting Balloon device due to unfavorable anatomy as determined by the physician and based on as assessment of vessel angles, size, length, and proximity to other vessels.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vessels with resistant PA stenosis were identified during catheterization and eligible vessels were randomized to Cutting Balloon or High Pressure Balloon Dilation
Device: Transcatheter Cutting Balloon therapy · Procedure: High Pressure Balloon Angioplasty
Acute Change in Minimum Lumen Diameter Immediately Post-intervention
The primary efficacy outcome is the percent change in minimum lumen diameter from pre-intervention to immediately post-intervention as measured by angiography.
Time frame: Pre-intervention to immediate post-intervention (approximately 10 minutes)
Percent Change in Minimum Lumen Diameter at 3 Months Post-intervention
Late percent change in minimum lumen diameter from pre-intervention to follow-up angiography.
Time frame: 3 months post-intervention
| Milestone | Cutting Balloon (CB) | High Pressure Balloon (HPB) |
|---|---|---|
| Started | 65 | 47 |
| Completed | 65 | 47 |
| Not completed | 0 | 0 |
The primary efficacy outcome is the percent change in minimum lumen diameter from pre-intervention to immediately post-intervention as measured by angiography.
| percentage change | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| Cutting Balloon | 85.1 ± 77.1 |
| High Pressure Balloon Dilation | 52.4 ± 66 |
Late percent change in minimum lumen diameter from pre-intervention to follow-up angiography.
| percent change | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| Cutting Balloon | 75.6 ± 97.8 |
| High Pressure Balloon Dilation | 42.2 ± 66.9 |
Collected over Patients were monitored for adverse events from the time of enrollment to follow-up assessment 2-4 months after the intervention.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients With Resistant Pulmonary Artery Stenosis | — | 0/73 (0%) | 16/73 (21.9%) |
| Event | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| Pulmonary EdemaCardiac disorders | 10/73 |
| Balloon RuptureCardiac disorders | 3/73 |
| Device malfunctionCardiac disorders | 2/73 |
| Balloon caught on stentCardiac disorders | 1/73 |
| Fracture of catheter shaftCardiac disorders | 1/73 |
| Intravascular tearCardiac disorders | 1/73 |
| Hemoptysis, hypotensionCardiac disorders | 1/73 |
| Heart BlockCardiac disorders | 1/73 |
Baseline data prior to vessel randomization
| Age, Categorical(Participants) | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| <=18 years | 72 |
| Between 18 and 65 years | 1 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| Female | 33 |
| Male | 40 |
| Race and Ethnicity Not Collected(Participants) | Patients With Resistant Pulmonary Artery Stenosis |
|---|
| Region of Enrollment(participants) | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| United States | 73 |
| Greater than 1/2 systemic RV pressure(Participants) | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| Count of participants | 60 |
| Regional decrease in pulmonary flow(Participants) | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| Count of participants | 58 |
| Elevated PA pressure (mean >20)(Participants) | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| Count of participants | 47 |
| Cyanosis in part due to PA stenosis(Participants) | Patients With Resistant Pulmonary Artery Stenosis |
|---|---|
| Count of participants | 19 |
Ran from Aug 2003 to primary completion in Mar 2009, 67 months.
Results were first posted in May 2018, 9 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stenosis, Pulmonary Artery